Drug Trial Radar · NCT07899346
Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Invivyd, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2a, randomized, double-blind, placebo-controlled, proof-of-concept study is being conducted to investigate the safety (whether there are any side effects), tolerability (if it does cause side effects, how well your body handles them), pharmacokinetics (PK) (how a drug is taken into your body, spread throughout, broken down, and eliminated), clinical activity (does the drug make patients feel better), immunogenicity (how the immune system responds to the drug), and serum virus neutralizing antibody response (antibodies that block a virus from infecting cells) of VYD2311, the investigational monoclonal antibody being studied, in adults with Long-COVID or Post-Vaccination Syndrome. Participants will receive an intravenous (IV) infusion on Day 1 of either the investigational drug or placebo followed by two intramuscular (IM) injections (a shot in the upper arm), one on day 30 and the other on Day 60. The IM injections will also either be investigational drug or placebo. The participants will be then asked to complete a 30-day follow up period and end the study on day 90.
Conditions
- Long COVID
- COVID-19 (SARS-CoV-2 Infection)
- COVID 19 Vaccine
- COVID Long
Interventions
VYD2311Drug
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with VYD2311
PlaceboDrug
Dosing via intravenous (IV) infusion on Day 1 follow by dosing via intramuscular (IM) injection on Day 30 and Day 60 with placebo (normal saline)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through Day 90Time frame: 90 days
- Serum concentrations of VYD2311 through Day 90Time frame: 90 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.